Dahl B H, Rindal R
Avdeling for kirurgisk onkologi Det Norske Radiumhospital, Montebello.
Tidsskr Nor Laegeforen. 1995 Jun 10;115(15):1830-3.
Extravasation of vesicant antitumour agents is a feared complication within oncologic therapy. The treatment is often meant to give palliation. Should extravasation occur it might further spoil the limited time many of these patients have left to live. The question is how to treat an extravasation injury without giving the patient an additional problem. The aim must be to remove the vesicant as soon as possible in a way that implies minimum morbidity and loss of function. At the Norwegian Radium Hospital, oncologists and plastic surgeons have cooperated on early surgical intervention, with good results. In our opinion, the problem arises when treatment is delayed. We present a retrospective study of 19 patients operated at the Norwegian Radium Hospital between 1986 and 1994, and discuss current methods of treatment.
发泡性抗肿瘤药物外渗是肿瘤治疗中令人担忧的并发症。治疗通常旨在缓解症状。一旦发生外渗,可能会进一步缩短许多此类患者所剩无几的生命时间。问题在于如何治疗外渗损伤而不给患者带来额外问题。目标必须是以将发病率和功能丧失降至最低的方式尽快清除发泡剂。在挪威镭医院,肿瘤学家和整形外科医生合作进行早期手术干预,取得了良好效果。我们认为,治疗延迟时问题就会出现。我们对1986年至1994年间在挪威镭医院接受手术的19名患者进行了回顾性研究,并讨论了当前的治疗方法。